Quest Diagnostics Incorporated earnings overview

DGX FY2026 Q2 · Calendar Q3 2026

Quest Diagnostics Incorporated

Quest Diagnostics delivered a strong Q2 2026, beating consensus on both revenue and EPS with double-digit organic volume growth and higher tests per requisition. Management raised full-year guidance for the second consecutive quarter, reflecting momentum across physician, hospital, and consumer health channels. AI-driven automation and advanced diagnostic portfolios -- including Haystack MRD, cardiometabolic panels, and Genius digital pathology -- are increasingly contributing to both top-line growth and productivity gains.